Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Daiichi Sankyo
Baxter
Farmers Insurance
Express Scripts
Merck
McKesson
Harvard Business School
Covington
Boehringer Ingelheim

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020235

« Back to Dashboard
NDA 020235 describes NEURONTIN, which is a drug marketed by Parke Davis and Pfizer Pharms and is included in three NDAs. It is available from four suppliers. There are two patents protecting this drug. Additional details are available on the NEURONTIN profile page.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-eight drug master file entries for this compound. One hundred and seven suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

Summary for NDA: 020235

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Anticonvulsants
Formulation / Manufacturing:see details

Pharmacology for NDA: 020235

Suppliers and Packaging for NDA: 020235

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEURONTIN
gabapentin
CAPSULE;ORAL 020235 NDA Parke-Davis Div of Pfizer Inc 0071-0803 0071-0803-24 100 CAPSULE in 1 BOTTLE (0071-0803-24)
NEURONTIN
gabapentin
CAPSULE;ORAL 020235 NDA Parke-Davis Div of Pfizer Inc 0071-0805 0071-0805-24 100 CAPSULE in 1 BOTTLE (0071-0805-24)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Dec 30, 1993TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Oct 25, 2017Product Flag?Substance Flag?Delist Request?Y

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength300MG
Approval Date:Dec 30, 1993TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Oct 25, 2017Product Flag?Substance Flag?Delist Request?Y

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength400MG
Approval Date:Dec 30, 1993TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Oct 25, 2017Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 020235



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Mallinckrodt
Dow
Citi
Chinese Patent Office
US Department of Justice
Argus Health
Express Scripts
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot